FKH has been a pioneer in the personalized medicine space since 2003 when we founded a special practice in this area to address the opportunities that would transform every sector in healthcare The dizzying advances in technology ($1,000 genome?) are now enabling policymakers to view personalized medicine as a potential solution to the economic crisis in paying for medical care, giving us the best possible chance to accelerate adoption in the clinic. Our work, with the Personalized Medicine Coalition (PMC), with The Age of Personalized Medicine.org, and with pharma companies and advocacy groups, has put us at the intersection where these approaches are gaining traction, and we’re proud to be part of key upcoming events.
The first is the 7th Annual Harvard Personalized Medicine Conference, Nov. 9-10 at the Harvard Medical School. We’re honored to serve on the organizing committee as well as once again being a sponsor of the PMC’s cocktail reception on Nov. 8, 6:00-9:00pm at the Hotel Commonwealth in Boston. This is a great opportunity to network with conference speakers and organizers. Registration is free for PMC members and $25 for non-members. Registration can be done online here.
The second event is a panel discussion and reception on November 16 to launch the third edition of PMC’s signature publication: The Case for Personalized Medicine. As with the previous two editions, FKH conducted the research, writing and design of this landmark document.
- Jennie Hunter-Cevera, Ph.D., Executive Vice President, RTI International
- Amy Abernethy, M.D., Director of the Duke Cancer Care Research Program
- Peter Collins, Ph.D., Vice President, Diagnostics, GlaxoSmithKline
- David King, Chief Executive Officer of the Laboratory Corporation of America (LabCorp)
Both of these events are excellent ways to meet the leaders of the rapidly growing personalized medicine space and we hope to see you there!